Currently they have 18 million cash. They should do some buyback to show some confidence. If they buy back 1 million stock ( $3.5 mil ), it will bring this stock to over 4 bucks.
They are forcasting about 11 mil. revenue this year and 18 in 2016.
So with 18 million cash and huge revenue stream, stock buy back of $ 3.5million is easily possible
The stock would be over 5 once they come up with semi-annual report. ( 5mil revenue for first half of 2015 ).
Story is dead..no one cares..management has failed to create any support for the business model..great science terrible board and terrible management. I hate to say it but it looks like they are all crooks..just dilute dilute dilute and sell nothing...same old third party re-embursement news/new patent..means nothing when you are paying people to sell whom cant get the job done..looks like another major dilution in 2016 and then another 10 for 1 reverse split..or the "Ken Berlin special" pathetic
I agree, Huge news. One of the largest providers opened the floodgates to cash flow and as more and more payers come on board offering to pay for their products, cash flow can only increase. How much? More than was possible before. I'm adding here just as ROSG is adding more and more tests to be covered by insurance. This can only be a good thing.
Sentiment: Strong Buy
This news is inconsequential and shows how little substance there is to this company. Personalize DX was purchased for less than $2,000,000. What possible contribution to earnings could a relatively worthless company provide Rosetta. If there were any reasonable expectation by ROSG or by Personalize DX of benefit to ROSG resulting from the purchase, the purchase price would have been far greater. Inconsequential news which is hyped by a company is always bad for the stock price. It is no different than the announcement by a buyer of goods or services announcing that it has an entering into an agreement with a "partner" to purchase goods and services from that partner. I guess that would make Wal-Mart my partner but neither I nor Wal-Mart have publicized our partnership yet.
Well, several of my small biotechnology holdings lost ground at the end of the day, so perhaps it was a group factor. Nevertheless, the news does get added to the list of positive reasons to own the stock, it's just a matter of watching how long the list gets, and when the positive reasons signal the company will have earnings and earnings growth.
Agreed. It is good news, as opposed to bad news, but since the news about the deal offers no solid indication of profitability, money mangers will continue to sit on their hands. However, with enough news like this, eventually one or two of those managers will move their hands out from under their as&^%es and put their fingers on the trigger, ready to pull it when real news that does suggest solid earnings is released.
News? Once again, no $ details. It all sounds good, but we've heard this sort of soft news so many times that we are no longer consider it meaningful. If stock moved up sharply, many would see it as an opportunity to sell. That known, why bother to buy?
So I did a quick search and found out that Lamberto Andreotti of BMY is the highest paid CEO in the pharma sector. His pay is a whopping $26.1 million annually. At ROSG we have a bargain with a CEO whose salary is just $500K. Or do we?
With BMY's $109 billion market cap, Andreotti's pay is 0.024% of market cap (about 1/5 of one tenth of one percent.) Meantime, Mr. Berlin's salary comes out to about 1.17% of market cap. If he were paid at the same percentage of market cap as the highest paid CEO in pharma, he'd be earning just over $10,000. Of course market cap used to be much higher for ROSG and much lower for BMY and so this isn't a fair comparison. ;-)
I suspect there are lots of measures of sentiment with regard to a stock's price action. One measure that I've come up with is the market reaction after a big move up our down. I think most of us already have the sense that any big gain is a good excuse to sell and therefore big gains don't hold. So to test that, I took the closing prices of the the last 6 months and figured the standard deviation of the change. Then I looked for days in which the net change (up or down) was greater than than the SD. Next I looked at the performance on the next day and for the sum of the following 5 days. If sentiment is negative, gains should be sold and losses should indicate "cut your losses." On the other hand, if sentiment is positive we should see the opposite reaction.
Over the course of 6 months, there were a total of 27 measures that indicated a negative sentiment and just 17 that indicated positive. So, looking at this period of time, it seems quite clear that sentiment is negative. On the upside, the last gain greater than 5.33% (the SD), was followed additional 1 and 5-day gains.
No, I haven't tested this to see if it has predictive power. Yet I think it meets the test of first-pass logic.
Funny and true!
We are held captive to the media releases these days. The management seems much more aware of that lately, and so I'm looking forward to some better news bulletins in the coming weeks. Until then, it looks like we are stuck in the doldrums.
It would seem that volume is the best predictor of volume. "Somebody must know something really important. The only one who doesn't know is me and so I'm going to buy now and find out why I bought later."
What if no one either was interested in buying or selling ROSG? Looks like that is the case today with only 300 shares traded 15 minutes into the day. 100 shares bid and ask? Oh, and then if wasn't for spamsters posting here, there'd be no activity on this board either.